AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14653296 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire (thermocycled)
Number of subjects: 60
Study 14653296 — intervention group
Group type: EXPERIMENTAL
Intervention: Z250 (thermocycled)
Number of subjects: 60
Study 11035314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise in diastolic blood pressure of >/=15 mm Hg with proteinuria
Number of subjects: 4302
Study 11035314 — intervention group
Group type: COMPARATOR
Intervention: Normotensive women without a rise in diastolic blood pressure or proteinuria
Number of subjects: 4302
Study 8831309 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus desflurane in N2O‐O2 (PDN)
Number of subjects: 20
Study 8831309 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (induction) plus desflurane in O2 (DD)
Number of subjects: 20
Study 8831309 — intervention group
Group type: COMPARATOR
Intervention: Propofol plus propofol infusion with N2O‐O2 (PPN)
Number of subjects: 20
Study 8831309 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus desflurane in O2 (PD)
Number of subjects: 20
Study 1454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 520
Study 1454160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 6324616 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 3 mg/kg po
Number of subjects: 12
Study 30036193 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Number of subjects: 0
Study 30036193 — intervention group
Group type: COMPARATOR
Intervention: Energy restriction
Number of subjects: 0
Study 30036193 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller studies on carbohydrate restriction
Number of subjects: 0
Study 26416494 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation during incision and drainage
Number of subjects: 209
Study 26416494 — intervention group
Group type: COMPARATOR
Intervention: No irrigation during incision and drainage
Number of subjects: 209
Study 25675566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion at Yaoyangguan (GV 3) under thermosensitive condition
Number of subjects: 57
Study 22390467 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual associative strategy
Number of subjects: 0
Study 22390467 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal associative strategy
Number of subjects: 0
Study 22390467 — intervention group
Group type: COMPARATOR
Intervention: Training with strategies utilizing unaffected cortical regions
Number of subjects: 0
Study 20518153 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI antidepressant drugs (e.g., Prozac)
Number of subjects: 0
Study 20518153 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs
Number of subjects: 0
Study 18333732 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary palliative care service (IPCS)
Number of subjects: 517
Study 18333732 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care (UC)
Number of subjects: 517
Study 15389280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG) 2 g/kg body weight over 2 days
Number of subjects: 10
Study 15389280 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort (not treated with IVIG)
Number of subjects: 10
Study 12873543 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin (CMV‐IGIV) prophylaxis
Number of subjects: 44
Study 12873543 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 44
Study 11135227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of 30 million autologous dendritic cells (DCs) per tumor after treatment with granulocyte‐macrophage‐colony stimulating factor and interleukin‐4.
Number of subjects: 10
Study 11135227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of dendritic cells (DCs).
Number of subjects: 10
Study 8982742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 20 micrograms for 10 days
Number of subjects: 0
Study 8982742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg three times a day for 5 days
Number of subjects: 0
Study 8982742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1621773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 2% every 12 hours with nasolacrimal occlusion
Number of subjects: 0
Study 1621773 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol 1.5% every 12 hours with nasolacrimal occlusion
Number of subjects: 0
Study 1621773 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol with nasolacrimal occlusion
Number of subjects: 0
Study 1621773 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.25% and Carbachol 1.5% every 12 hours with nasolacrimal occlusion
Number of subjects: 0
Study 6239893 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% minoxidil solution
Number of subjects: 16
Study 6239893 — intervention group
Group type: COMPARATOR
Intervention: 0%, 1%, 3% minoxidil solutions
Number of subjects: 16
Study 6239893 — intervention group
Group type: EXPERIMENTAL
Intervention: minoxidil (all concentrations)
Number of subjects: 16
Study 31324520 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 400
Study 29223722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib (40 mg diluted in 2 mL, given 30 minutes before surgery and every 12 hours for 48 hours)
Number of subjects: 160
Study 29223722 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 mL normal saline given at the same intervals)
Number of subjects: 160
Study 26920599 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin monotherapy
Number of subjects: 1000
Study 26920599 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Anticoagulation (OAC) monotherapy
Number of subjects: 1000
Study 26920599 — intervention group
Group type: COMPARATOR
Intervention: Aspirin + Clopidogrel
Number of subjects: 1000
Study 26920599 — intervention group
Group type: COMPARATOR
Intervention: OAC + Clopidogrel
Number of subjects: 1000
Study 26920599 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC monotherapy
Number of subjects: 1000
Study 25300457 — intervention group
Group type: EXPERIMENTAL
Intervention: S.MS self-management training program
Number of subjects: 64
Study 25300457 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochures)
Number of subjects: 64
Study 22207715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 103
Study 22207715 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (Control)
Number of subjects: 103
Study 20087377 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet (12% of total daily energy intake)
Number of subjects: 87
Study 20087377 — intervention group
Group type: COMPARATOR
Intervention: Habitual (control) diet
Number of subjects: 87
Study 17134774 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study 17134774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 11106134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam SR (1.5 mg)
Number of subjects: 13
Study 11106134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (3 mg taken three times daily)
Number of subjects: 13
Study 11106134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg taken three times daily)
Number of subjects: 13
Study 11106134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9347095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol
Number of subjects: 18
Study 9347095 — intervention group
Group type: COMPARATOR
Intervention: Nonalcohol beverage (Control)
Number of subjects: 18
Study 8474819 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified rice cereal
Number of subjects: 515
Study 8474819 — intervention group
Group type: COMPARATOR
Intervention: Unfortified rice cereal
Number of subjects: 515
Study 8474819 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified formula
Number of subjects: 515
Study 2878030 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 200
Study 2878030 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan
Number of subjects: 200
Study 30541376 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive Life Plan (RLP)‐based counselling
Number of subjects: 201
Study 30541376 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 201
Study 27500351 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 59
Study 27500351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 24240666 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) combined with prednisone
Number of subjects: 211
Study 24240666 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 211
Study 21497520 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education (PE)
Number of subjects: 118
Study 20545477 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia instructional video about MPS with supplemental handouts
Number of subjects: 62
Study 20545477 — intervention group
Group type: COMPARATOR
Intervention: Trigger-point dry needling and muscle-stretch exercise regimen
Number of subjects: 62
Study 18751497 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate test formulation (10 mg)
Number of subjects: 24
Study 18751497 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate reference formulation (10 mg)
Number of subjects: 24
Study 15973092 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection-model training with instructional videotape and visual feedback on injection accuracy
Number of subjects: 30
Study 15973092 — intervention group
Group type: COMPARATOR
Intervention: Control group studying technical aspects of injections
Number of subjects: 30
Study 12795748 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone 2 x 200 mg + amoxycillin 2 x 1 g + omeprazole 2 x 20 mg/day
Number of subjects: 123
Study 12795748 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone 2 x 50 mg + amoxycillin 2 x 1 g + omeprazole 2 x 20 mg/day
Number of subjects: 123
Study 10381910 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐11 40 microgram. kg‐1. wk‐1 (2 or 5 times weekly for 3 weeks)
Number of subjects: 76
Study 10381910 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐11 16 microgram. kg‐1. wk‐1 (5 times weekly for 3 weeks)
Number of subjects: 76
Study 10381910 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐11 16 microgram. kg‐1. wk‐1 (2 times weekly for 3 weeks)
Number of subjects: 76
Study 10381910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 8532271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day)
Number of subjects: 186
Study 8532271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 8532271 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal uterine artery flow velocity waveforms
Number of subjects: 186
Study 1669669 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (30 mg/kg per day)
Number of subjects: 13
Study 29676592 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) treatment every four weeks for four months
Number of subjects: 9
Study 29676592 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated lesions)
Number of subjects: 9
Study 28573748 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM) using noxious cold (6 °C) water before thermal grill application.
Number of subjects: 0
Study 28573748 — intervention group
Group type: COMPARATOR
Intervention: Control run with 33 °C water.
Number of subjects: 0
Study 28573748 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group rated pain and unpleasantness of a thermal grill with innocuous alternating warm (42 °C) and cool (18 °C) bars.
Number of subjects: 0
Study 28573748 — intervention group
Group type: COMPARATOR
Intervention: Control group rated a grill with all bars controlled to a noxious temperature (45 °C).
Number of subjects: 0
Study 25945550 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial bright light (TBL) treatment; administered as intermittent light exposures (4 × 12 min) during the 7-day post-travel period after an eastward transatlantic flight.
Number of subjects: 55
Study 25945550 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment; details not specified.
Number of subjects: 55
Study 23322564 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PLEX) treatment
Number of subjects: 42
Study 23322564 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 42
Study 21293964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Body Negative Pressure (LBNP)
Number of subjects: 1
Study 21293964 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgravity
Number of subjects: 1
Study 21293964 — intervention group
Group type: COMPARATOR
Intervention: Pre-flight condition
Number of subjects: 1
Study 21293964 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-flight condition
Number of subjects: 1
Study 19627273 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 337
Study 19627273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 18046594 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate Diet (VLCKD)
Number of subjects: 0
Study 18046594 — intervention group
Group type: COMPARATOR
Intervention: Low Fat Diet (LFD)
Number of subjects: 0
Study 15943939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (4-24 mg)
Number of subjects: 21
Study 15943939 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone (20-100 mg)
Number of subjects: 21
Study 11883347 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous delivery of the placenta (group 1)
Number of subjects: 375
Study 11883347 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual removal of the placenta (group 2)
Number of subjects: 375
Study 10418538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 471
Study 10418538 — intervention group
Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 471
Study 10418538 — intervention group
Group type: COMPARATOR
Intervention: Desipramine hydrochloride
Number of subjects: 471
Study 8614301 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal/Cod Liver Oil (CLO)
Number of subjects: 134
Study 8614301 — intervention group
Group type: EXPERIMENTAL
Intervention: Whale Oil
Number of subjects: 134
Study 8614301 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal Oil
Number of subjects: 134
Study 8614301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod Liver Oil (CLO)
Number of subjects: 134
Study 8614301 — intervention group
Group type: COMPARATOR
Intervention: No Oil (Control)
Number of subjects: 134
Study 1704879 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens
Number of subjects: 0
Study 1704879 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 6789720 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% cromolyn solution
Number of subjects: 26
Study 6789720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31622643 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 0
Study 31622643 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 30971750 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice treated with invertase, glucose oxidase/catalase (glucose 0.05 g; gluconate 18.2 g)
Number of subjects: 30
Study 30971750 — intervention group
Group type: COMPARATOR
Intervention: Untreated apple juice (free glucose 8.5 g; bound glucose 6.7 g; gluconate below detection limit)
Number of subjects: 30
Study 27718013 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA administration
Number of subjects: 28
Study 27718013 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 28
Study 25956354 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy (BBAT)
Number of subjects: 15
Study 23565815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g of omega-3 fatty acids (O3) per day for 4 weeks
Number of subjects: 57
Study 23565815 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil placebo for 4 weeks
Number of subjects: 57
Study 21150665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan disc arthroplasty
Number of subjects: 46
Study 21150665 — intervention group
Group type: COMPARATOR
Intervention: ProDisc-C arthroplasty
Number of subjects: 46
Study 19657503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance and movement teaching method
Number of subjects: 0
Study 19657503 — intervention group
Group type: COMPARATOR
Intervention: Traditional pharmacy lecture and PowerPoint slides
Number of subjects: 0
Study 17334533 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dosage: 13.6 +/- 6.9 mg)
Number of subjects: 12
Study 17334533 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean dosage: 5.8 +/- 3.8 mg)
Number of subjects: 12
Study 15201559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5 mg
Number of subjects: 24
Study 15201559 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine LA 30 mg
Number of subjects: 24
Study 15201559 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 24
Study 11296176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal noninvasive mechanical ventilation (NIMV)
Number of subjects: 36
Study 9336752 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vacuum extraction (n = 164)
Number of subjects: 322
Study 9336752 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vacuum extraction (n = 158)
Number of subjects: 322
Study 7515345 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense porridge made liquid by adding amylase-rich flour from germinated wheat (test diet)
Number of subjects: 78
Study 7515345 — intervention group
Group type: COMPARATOR
Intervention: Unaltered thick porridge of similar energy density (control 1 diet)
Number of subjects: 78
Study 7515345 — intervention group
Group type: COMPARATOR
Intervention: Porridge made liquid with addition of water to have the same viscosity as the test diet but of lower energy (control 2 diet)
Number of subjects: 78
Study 3270664 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-01 applied site (T)
Number of subjects: 147
Study 3270664 — intervention group
Group type: COMPARATOR
Intervention: Placebo-applied site (P)
Number of subjects: 147
Study 3270664 — intervention group
Group type: COMPARATOR
Intervention: Control site (C)
Number of subjects: 147
Study 28671552 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 5583
Study 28671552 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES)
Number of subjects: 5583
Study 27004411 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched soy extract (117.4 mg/day isoflavone aglycone equivalents) for 12 weeks
Number of subjects: 170
Study 27004411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 25341140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrographic phase MDCT urography
Number of subjects: 121
Study 25341140 — intervention group
Group type: COMPARATOR
Intervention: Pyelographic phase MDCT urography
Number of subjects: 121
Study 23528159 — intervention group
Group type: EXPERIMENTAL
Intervention: V + C (oral vinorelbine at 80 mg/m², then 60 mg/m² after first cycle, and capecitabine at 1,000 mg/m² bid from days 1 to 14)
Number of subjects: 139
Study 23528159 — intervention group
Group type: EXPERIMENTAL
Intervention: V↔C (oral vinorelbine weekly and capecitabine at 1,000 mg/m² bid from days 1 to 14)
Number of subjects: 139
Study 23528159 — intervention group
Group type: EXPERIMENTAL
Intervention: D + C (docetaxel at 75 mg/m² on day 1 and capecitabine at 1,000 mg/m² bid from days 1 to 14)
Number of subjects: 139
Study 19952980 — intervention group
Group type: EXPERIMENTAL
Intervention: GARDASIL (0.5 mL dose at day 1, month 2, and month 6) with REPEVAX (0.5 mL dose on day 1 or month 1)
Number of subjects: 843
Study 19952980 — intervention group
Group type: EXPERIMENTAL
Intervention: REPEVAX administered concomitantly with GARDASIL
Number of subjects: 843
Study 19952980 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of GARDASIL and REPEVAX
Number of subjects: 843
Study 18584876 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with 4 mg triamcinolone acetonide (TA) injected into the silicone-filled vitreous cavity
Number of subjects: 75
Study 18584876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjunctive treatment)
Number of subjects: 75
Study 18584876 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with 4 mg triamcinolone acetonide (TA)
Number of subjects: 75
Study 15801919 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged lamivudine treatment
Number of subjects: 85
Study 11821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (100 microg/kg per chemotherapy cycle)
Number of subjects: 310
Study 11821454 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/d)
Number of subjects: 310
Study 10518177 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT antagonist metergoline
Number of subjects: 14
Study 10518177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8834843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial meningitis
Number of subjects: 0
Study 8834843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial meningitis (fatal outcome)
Number of subjects: 0
Study 8834843 — intervention group
Group type: COMPARATOR
Intervention: Lymphocytic meningitis
Number of subjects: 0
Study 2202549 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release indomethacin tablets, 75 mg given at night
Number of subjects: 80
Study 2202549 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release indomethacin capsules, 75 mg given 3-times daily
Number of subjects: 80
Study 7247635 — intervention group
Group type: EXPERIMENTAL
Intervention: Food coloring
Number of subjects: 11